SYROS PHARMACEUTICALS, INC.

Analyst Reco. Syros Pharmaceuticals, Inc.

Equities

SYRS

US87184Q2066

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
5.04 ^USD	-1.18%		+11.01%	-35.30%

Apr. 09	Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	MT
Apr. 09	Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JMP Securities Adjusts Price Target on Syros Pharmaceuticals to $15 From $16, Maintains Market Outperform Rating	23-05-11	MT
Oppenheimer Adjusts Syros Pharmaceuticals Price Target to $13 From $15, Maintains Outperform Rating	23-03-03	MT
Piper Sandler Cuts Price Target on Syros Pharmaceuticals to $20 From $27, Reiterates Overweight Rating	23-01-05	MT
Oppenheimer Adjusts Syros Pharmaceuticals Price Target to $15 From $30, Maintains Outperform Rating	22-11-15	MT
JMP Securities Cuts Price Target on Syros Pharmaceuticals to $16 From $40, Maintains Market Outperform Rating	22-11-15	MT
Oppenheimer Adjusts Syros Pharmaceuticals Price Target to $3 From $9, Maintains Outperform Rating	22-08-10	MT
HC Wainwright Adjusts Price Target on Syros Pharmaceuticals to $6 From $10, Reiterates Buy Rating	22-07-12	MT
HC Wainwright Adjusts Price Target on Syros Pharmaceuticals to $10 From $15, Reiterates Buy Rating	22-05-17	MT
Alliance Global Adjusts Price Target on Syros Pharmaceuticals to $10 From $14, Reiterates Buy Rating	22-05-17	MT
SYROS PHARMACEUTICALS : Roth Capital Adjusts Price Target on Syros Pharmaceuticals to $23 From $20, Maintains Buy Rating	21-09-23	MT
SYROS PHARMACEUTICALS : Oppenheimer Adjusts Syros Pharmaceuticals PT to $9 From $13, Maintains Outperform Rating	21-09-21	MT
SYROS PHARMACEUTICALS : Wedbush Adjusts Syros Pharmaceuticals' Price Target to $8 From $10, Maintains Neutral Rating	20-12-07	MT
SYROS PHARMACEUTICALS : HC Wainwright Upgrades Syros Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $15 From $11	20-11-04	MT
Syros Pharmaceuticals Announces New Data from Phase 2 Trial of SY-1425 in Combination with Azacitidine Demonstrating High Response Rates, Rapid Onset of Action and Favorable Tolerability Profile in RARA-Positive Newly Diagnosed Unfit AML Patients	19-10-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer